vimarsana.com

Latest Breaking News On - Therapeutics company profile - Page 2 : vimarsana.com

ADC Therapeutics (NYSE:ADCT) Research Coverage Started at Cantor Fitzgerald

Investment analysts at Cantor Fitzgerald began coverage on shares of ADC Therapeutics (NYSE:ADCT – Get Free Report) in a report released on Thursday, Marketbeat.com reports. The brokerage set an “overweight” rating on the stock. A number of other brokerages have also issued reports on ADCT. Guggenheim reissued a “buy” rating on shares of ADC Therapeutics […]

Viking Therapeutics, Inc (NASDAQ:VKTX) Receives $112 38 Average Target Price from Brokerages

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have been assigned an average rating of “Buy” from the nine brokerages that are currently covering the stock, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average […]

Viking Therapeutics, Inc (NASDAQ:VKTX) Receives $112 38 Average Price Target from Analysts

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have received an average rating of “Buy” from the nine ratings firms that are covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year […]

G1 Therapeutics (GTHX) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of G1 Therapeutics (NASDAQ:GTHX – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. Needham & Company LLC currently has a $12.00 target price on the stock. GTHX has been the topic of a number of other reports. Wedbush restated […]

RAPT Therapeutics, Inc (NASDAQ:RAPT) Receives Average Rating of Hold from Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Free Report) has received a consensus recommendation of “Hold” from the thirteen analysts that are currently covering the company, Marketbeat Ratings reports. Nine analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month target price among […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.